October 14, 2008 – Medtronic released, at TCT 2008, new data from the ENDEAVOR clinical program that reinforces the consistently strong performance of the company’s Endeavor drug-eluting stent (DES) across diverse patient populations affected by coronary artery disease.
One-year results from the ENDEAVOR-Five registry – including those for subsets of diabetics and patients with acute myocardial infarction (AMI) – demonstrate that the Endeavor DES performs comparably in a real-world population of patients with complex disease and in specific patient subsets.
“Registries generally enroll more challenging ‘real-world’ patients than randomized trials,” said professor Martin Rothman of the U.K.’s London Chest Hospital and one of ENDEAVOR-Five’s principal investigators.
“Approximately 70 percent of the 8,314 patients enrolled in E-Five had complex cardiovascular disease, including diabetes, small vessels and long lesions, and a significant number were acute coronary syndrome or AMI. Despite the higher complexity of the patients enrolled in this registry, the outcomes at 12 months were excellent; the rates of MACE, TLR, cardiac death, MI and stent thrombosis were remarkably low and consistent with findings from the ENDEAVOR clinical trial program overall.”
The 12-month target lesion revascularization (TLR) rate for all patients in E-Five (n=8,314) was 4.5 percent; for the subset of diabetics (n=2,563), 5.3 percent; for the AMI patients (n=1,077), 3.2 percent; and for the high-risk patients (n=5,824), 5.0 percent.
Five-year results from the ENDEAVOR-I trial complement and corroborate a vast array of consistently compelling data, which supports the durable efficacy of the Endeavor DES over the long term, said Medtronic.
Medtronic’s Endeavor stent is associated with TLR rates, which stop increasing at three years. Randomized controlled trials of other drug-eluting stents show a continued increase in TLR, reducing the durability of benefit. More compelling is how the ENDEAVOR-I TLR plateau is replicated on a larger scale in ENDEAVOR-II, the device’s pivotal study. With data out to four years, exactly the same curve is apparent, and TLR stops increasing at 36 months.
For more information: www.medtronic.com
July 02, 2024 
